Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.58 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7312208 | 1.00 | MMEL1 (0.58) | MMEL1MMEACE | |
| SCHEMBL7310804 | 1.00 | MMEL1 (0.58) | MMEL1MMEACE | |
| SCHEMBL7340627 | 0.95 | MMEL1 (0.53) | MMEL1MME | |
| SCHEMBL7314722 | 0.95 | MMEL1 (0.53) | MMEL1 | |
| SCHEMBL7309965 | 0.95 | MMEL1 (0.53) | MMEL1 | |
| SCHEMBL7314983 | 0.94 | MMEL1 (0.50) | MMEL1 | |
| SCHEMBL7318630 | 0.93 | MMEL1 (0.53) | MMEL1 | |
| SCHEMBL7309952 | 0.93 | MMEL1 (0.53) | MMEL1 | |
| SCHEMBL7320009 | 0.92 | MMEL1 (0.48) | MMEL1 | |
| SCHEMBL7311806 | 0.91 | MMEL1 (0.51) | MMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5155100-A | Treating cardiovascular disorders in mammals | CIBA-GEIGY CORPORATION (US) | 1992-10-13 | — | — | US | claimed |
| US-20160115186-A1 | PHOSPHORIC ACID/PHOSPHONIC ACID DERIVATIVES AND MEDICINAL USES THEREOF | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115186-A1 | PHOSPHORIC ACID/PHOSPHONIC ACID DERIVATIVES AND MEDICINAL USES THEREOF | P2RY1, SQLE, PHOSPHO1 | MMEL1 4431/4885MME 4329/4885ACE 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.